MNG847
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.478
- ESTROGEN_RESPONSE_EARLY+0.434
- CHOLESTEROL_HOMEOSTASIS+0.416
- ESTROGEN_RESPONSE_LATE+0.401
- PANCREAS_BETA_CELLS+0.367
- APICAL_SURFACE+0.366
- KRAS_SIGNALING_DN+0.306
- TGF_BETA_SIGNALING+0.292
- HYPOXIA+0.277
- APOPTOSIS+0.266
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.536
- DNA_REPAIR-0.440
- E2F_TARGETS-0.410
- MYC_TARGETS_V2-0.391
- MYC_TARGETS_V1-0.384
- MITOTIC_SPINDLE-0.348
- ADIPOGENESIS-0.345
- G2M_CHECKPOINT-0.336
- INTERFERON_ALPHA_RESPONSE-0.315
- WNT_BETA_CATENIN_SIGNALING-0.304
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG113 | — | — | 0.906 |
| 2 | MNG591 | — | — | 0.887 |
| 3 | MNG931 | — | — | 0.869 |
| 4 | TCGA-55-6984-01A-11R-1949-07 | — | cohortA1 | 0.863 |
| 5 | MNG130 | — | — | 0.854 |
| 6 | MNG789 | — | — | 0.846 |
| 7 | MNG836 | — | — | 0.844 |
| 8 | SRR1315866 | GTEX | — | 0.841 |
| 9 | MNG330 | — | — | 0.839 |
| 10 | MNG508 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.478 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.434 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.416 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.401 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.367 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.366 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.306 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.292 | Inavolisib | — uncovered |
| HYPOXIA | 0.277 | Idelalisib | — uncovered |
| APOPTOSIS | 0.266 | Idelalisib | — uncovered |
| COAGULATION | 0.264 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.242 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.234 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.219 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.213 | Idelalisib | — uncovered |
| MYOGENESIS | 0.166 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.154 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.135 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.117 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.116 | Inavolisib | — uncovered |